Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy for hematologic malignancies 1 . In patients undergoing allogeneic HSCT, donor-derived T-cell activation leads to widespread host tissue damage resulting in a clinicopathologic syndrome known as graft-versus-host disease (GVHD) 2 . However, T-cell-mediated attack of the recipient can also be beneficial as it can eliminate malignant cells that might have escaped radiation or chemotherapy, a process known as the graft-versus-tumor (GVT) effect 3 . Therefore, identifying mechanisms to control GVHD yet maintain GVT effects is of critical importance to improve the success rate of allogeneic HSCT treatment.
Allogeneic T-cell activation occurs in several phases after HSCT. The conditioning regimen contributes to priming of the immune response by inducing inflammation, leading to activation of antigen presenting cells (APC)s, expansion and activation of donor T-cells by host
APCs, and finally, trafficking of activated T-cells to the GVHD target tissues where inflammation and tissue destruction occur 4, 5 . In addition to TCR stimulation by allogeneic MHC, costimulation provided by APCs (B7 family, the TNF receptor family, and adhesion molecules such as LFA-1) 6-9 induce full T-cell activation, proliferation, and cytokine production 10 . Costimulatory signal blockade during allogeneic HSCT has shown that these signals play an important role in the pathophysiology of acute GVHD 3, 11 .
Co-stimulatory signals received from non-APCs could also promote the function of Tcells. For example, the engagement of NKG2D with NKG2D ligands expressed on a variety of cells can promote the activity of CD8 + T-cells under specific settings 12 . NKG2D is expressed by subsets of NK cells, NKT-cells, γδ T-cells, and CD8 + T-cells [12] [13] [14] [15] . NKG2D recognizes several
MHC-related proteins with limited constitutive expression, which are up-regulated on
For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From transformed, infected, and "stressed" cells 12, [15] [16] [17] . These ligands include the RAE-1, H60, and Mult1 proteins in rodents, and the MIC and ULBP/RAET families in humans [18] [19] [20] [21] . As many neoplastic cells constitutively express NKG2D ligands, NKG2D expression by NK cells and Tcells play an important role in anti-tumor responses 17 . NKG2D also facilitates TCR-mediated CD8 + T-cell activation in inflammatory states where NKG2D ligands are induced on normal tissue, such as in type I diabetes and in solid organ transplantation [22] [23] [24] .
Although NKG2D ligands are upregulated upon myeloablative conditioning prior to allogeneic HSCT treatment [25] [26] [27] [28] [29] , the role that NKG2D expression on CD8 + T-cells play after allogeneic HSCT is unknown. Since activated CD8 + T-cells express NKG2D, we sought to investigate how NKG2D expression might affect CD8 + T-cell responses in allogeneic HSCT.
Given that NKG2D ligands are expressed on both stressed normal tissue and on malignant cells, we hypothesized that NKG2D plays an important role in mediating GVHD and GVT effects during allogeneic HSCT. In this manuscript, we provide data supporting a role for NKG2D on CD8 + T-cells in mediating GVHD and GVT effects, which could be therapeutically exploited to separate the two processes.
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Methods
Mice. NKG2D knockout (KO) mice were described previously 30 and bred in our institution.
C57BL/6, C57BL/6.SJL, C3H.SW, and Balb/c were purchased from the National Cancer institute or Charles River Laboratories. Perforin KO and P14 TCR transgenic mice were a kind gift from Drs. Edward Behrens and John Wherry, respectively (University of Pennsylvania).
Mice of 8-12 weeks of age were used and all experiments were performed with age-and sexmatched mice. Animal maintenance and experimentation were performed in accordance with the Institutional animal care and use committee at University of Pennsylvania, Philadelphia.
Peripheral blood from patients undergoing allogeneic HSCT were collected using a protocol approved by our Institutional Review Board, in accordance with the Declaration of Helsinki. Dead Cell Stain Kit. All cell culture reagents and chemicals were purchased from Invitrogen (Grand Island, NY) and Sigma Aldrich (St. Louis, MO), respectively, unless otherwise specified.
Reagents
The A20 cell line was transduced with luciferase and cultured as described previously 31 Triplicate wells were averaged and percent lysis was calculated from the data using the following equation: % specific lysis =100 x (spontaneous death bioluminescence -test bioluminescence)/(spontaneous death bioluminescence -maximal killing bioluminescence).
Fluorescence microscopy and histological analysis. The colon was harvested from experimental and control mice, washed in PBS, flash frozen in OCT media and sectioned at 10 µm by the 
Results

NKG2D is induced on CD8 + T-cells upon TCR stimulation and augments CD8 + T-cellmediated GVHD
Although naïve murine CD8 + T-cells do not express NKG2D 13 We next tested whether human CD8 + T-cells from allogeneic HSCT patients also express NKG2D. CD8 + T-cells from 35 blood samples of allogeneic HSCT patients were analyzed for NKG2D expression. The CD8 + T-cells from all patients expressed NKG2D. Interestingly, although not statistically significant, patients with active GVHD at the time of the blood draw trended towards higher levels of NKG2D compared to patients without GVHD (Supplemental Figure 2 ). These data suggest that our findings that NKG2D expression by CD8 + T-cells augments GVHD pathogenesis in mice may be clinically relevant.
NKG2D KO CD8 + T-cells exhibit reduced survival and cytotoxicity in a cell-intrinsic manner
To test the function of NKG2D KO CD8 + T-cells in a cell-intrinsic manner, we performed BMT KO CD8 + T-cells also showed reduced cytotoxicity against A20 leukemia targets when removed from mice either transplanted singly or with a mixture of WT and NKG2D KO CD8 + T-cells ( Figure 3F ). The cytotoxicity of WT CD8 + T-cells against A20 cells was reduced in vitro by the addition of anti-NKG2D antibody, suggesting that NKG2D augments killing of A20 cells ( Figure 3F ). Together, these data suggest that while decreased survival and cytotoxicity is the [36] [37] [38] . Importantly, we found that in the B6 Balb/c model, GVHD-induced weight loss, clinical score, and mortality mediated by CD8 + T-cells from perforin KO mice were partially reduced compared to CD8 + T-cells from WT mice (Supplemental Figure 3) . If NKG2D-mediated protection was due to reduced cytotoxic activity of CD8 + T-cells in allogeneic BMT mice, we reasoned that perforin deficiency would be unable to further enhance the protective effects of NKG2D blockade. Indeed, the combination of perforin deficiency and NKG2D blockade was not additive in attenuating GVHD-induced weight loss or clinical score (Supplemental Figure 3) .
These data suggest that NKG2D blockade, at least in part, mediates its protective effect by suppressing the cytotoxic activity of CD8 + T-cells in allogeneic HSCT mice.
Prolonged NKG2D blockade attenuates both GVHD and GVL responses
Given its role in cytotoxic responses, we predicted that NKG2D would be required for optimal GVT responses. Lethally irradiated Balb/c mice were transplanted with BM and FACS-sorted Figure 6G-H) . Thus, the expression of RAE-1γ, which correlated with tissue damage, was not sustained when mice were treated with anti-NKG2D antibody.
Transient NKG2D blockade attenuates GVHD while preserving GVL effects
Given that RAE-1γ expression was reduced with short-term NKG2D blockade compared to isotype control, we reasoned that prolonged anti-NKG2D antibody treatment would not be necessary for protection against GVHD. However, early cessation of anti-NKG2D antibody treatment might allow NKG2D-mediated GVT effects to resume, since RAE-1 is constitutively it is possible that NKG2D is required for optimal IL-15 signaling. A recent study showed that NKG2D enhances IL-15-mediated PI3K activation and promotes the survival of CD8 + T-cells 39 .
Given that IL-15 signaling is critical in GVHD pathogenesis 40 , NKG2D expression by CD8 + Tcells might provide a survival boost by potentiating the effects of IL-15 in this setting. This is consistent with data demonstrating that the acute induction of NKG2D ligands can promote cytotoxic effects by T-cells 41 . Given that blockade of perforin-mediated killing activity significantly improved GVHD-induced mortality in our model, the decrease in cytotoxic function by NKG2D blockade likely contributed to the alleviation of GVHD severity. Although mortality could not be used as a parameter to test the additive nature of NKG2D blockade and perforin deficiency, this notion is consistent with our data demonstrating that perforin deficiency does not provide further benefit to anti-NKG2D antibody treatment in the alleviation of GVHD.
NKG2D may enhance CD8 + T-cell-mediated cytotoxic function through its costimulatory activity. Although a short splice variant of NKG2D has been reported to associated with DAP12 in IL-2-activated murine NK cells 42 , in mouse and human CD8 + T-cells, NKG2D signals though DAP10 43 , which contains a YXXM motif similar to that of CD28. Thus, costimulatory signals provided by NKG2D can augment TCR signaling [44] [45] [46] potentially leading to enhanced cytotoxicity of NKG2D ligand expressing epithelial cells during GVHD. Alternatively, the cytotoxicity of NKG2D + CD8 + T-cells could occur in a TCR-independent manner. For example, IL-15 has been shown to upregulate NKG2D and DAP10 expression and to augment ERK phosphorylation, which allows NKG2D to mediate cytotoxicity in a TCR-independent manner in celiac disease 47 . Moreover, culturing human CD8 + T-cells with high doses of IL-2, 48, 49 .
IFN-γ, and CD3 enables these cells to kill in an NKG2D-dependent but TCR-independent
Given the important role of NKG2D in augmenting the cytotoxic function of CD8 + Tcells during GVHD, we predicted that NKG2D blockade would be counterproductive for GVT effects. CD8 + T-cells that express the NKG2D receptor have been shown to acquire potent cytolytic ability against leukemia cells 24, 48, 49 Consistent with these findings, genetic deficiency of NKG2D or prolonged NKG2D blockade resulted in an attenuated ability of CD8 + T-cells to control A20 tumor growth. These data suggest that NKG2D not only plays a role in GVHD but also in GVT effects against NKG2D ligand-expressing tumors. 
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